17,261 trials
Epithelial Ovarian Cancer
Primary: Overall Response Rate (CR+PR) Per Investigator Assessment Based on GOG-RECIST Criteria — 7; 4; 3; 14 Participants
Prostate Cancer
Primary: Number of Patients Experiencing Decline in Prostate-specific Antigen — 2 Participants
Autosomal Dominant Polycystic Kidney Disease
Primary: Mean Change From Baseline in Measured Glomerular Filtration Rate (mGFR) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. — -8.0; -6.2; -0.7; 0.1…
Varicella
Primary: Antibody Titers Against Varicella Zoster Virus (VZV) — 172.6; 154.3 Titers
Traumatic Brain Injury · Posttraumatic Epilepsy
Primary: Extended Glasgow Outcome Scale (GOS-E) Score — 4.2; 4.3 GOS-E Score
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants
Multiple Myeloma
Primary: The Percent of Patients With Minimal Residual Disease (MRD) Status Changing to Negative at Day 100 (Post-AHCT), Among Patients With MRD Positive at the End of Induction…
Renal Cell Carcinoma
Primary: Progression-free Survival — 8.3 months
Influenza
Primary: Ratios of Geometric Mean Titer (GMT) in Subjects (6 to <48 Months Old) After Receiving Two Doses of Either TIVc or TIVe Vaccine — 7.82; 5.5; 5.93; 3.69 Ratios
Squamous Cell Carcinoma of the Head and Neck
Primary: Objective Response Rate (ORR) — 0; 2 participants
Breast Cancer
Primary: Maximum-tolerated Dose (Phase I) — 1; 3 Participants
Breast Cancer
Primary: Number of Patients With Pathological Complete Response Rate — 35; 24 Participants — p=0.019
Glioblastoma Multiforme
Primary: Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Dasatinib in Combination With Bevacizumab (Phase I) — 0; 0; 0; 0…
Iron Deficiency Anemia
Primary: Changes in Blood Markers — -.38; -.08 mg/dL
Kidney Transplant
Primary: Maximum Observed Serum Concentration (Cmax) of Belatacept — 151 micrograms per milliliter